3-cyclohexyl-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-6-oxo-6H-pyridazin-1-yl]-propionic acid → 3-cyclohexyl-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-6-oxo-6H-pyridazin-1-yl]-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-propionamide

Participants

Reaction Steps

Using the method described in Example 49, 3-cyclohexyl-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-6-oxo-6H-pyridazin-1-yl]-propionic acid (Intermediate 99) and 1-(3-amino-pyrazol-1-yl)-2-methyl-propan-2-ol (Intermediate 1) afforded 3-cyclohexyl-2-[4-(2,3-dihydro-benzo[1,4]dioxin-5-yloxy)-6-oxo-6H-pyridazin-1-yl]-N-[1-(2-hydroxy-2-methyl-propyl)-1H-pyrazol-3-yl]-propionamide as an off-white solid (40 mg, 22%); ES+-HRMS m/e calcd for C28H35N5O6 [M+H+] 538.2660 found 538.2660. 1H NMR (300 MHz, CDCl3) δ ppm 0.73-1.34 (m, 6H), 1.16 (br. s., 3H), 1.16 (br. s., 3H), 1.54-1.85 (m, 5H), 1.96-2.29 (m, 2H), 3.99 (s, 2H), 4.20-4.37 (m, 4H), 5.59-5.79 (m, 1H), 6.00 (d, J=2.7 Hz, 1H), 6.64-6.77 (m, 2H), 6.78-6.95 (m, 2H), 7.32 (s, 1H), 7.96 (d, J=2.7 Hz, 1H), 8.77 (br. s., 1H).

Provenance & Evidence